FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2236504019> ?p ?o ?g. }

• W2236504019 endingPage "e0004364" @default.
• W2236504019 startingPage "e0004364" @default.
• W2236504019 abstract "To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD). While a number of candidate drugs have shown limited efficacy in vitro and/or in non-human primate studies, differences in experimental methodologies make it difficult to compare their therapeutic effectiveness. Using an in vitro model of Ebola Zaire replication with transcription-competent virus like particles (trVLPs), requiring only level 2 biosafety containment, we compared the activities of the type I interferons (IFNs) IFN-α and IFN-ß, a panel of viral polymerase inhibitors (lamivudine (3TC), zidovudine (AZT) tenofovir (TFV), favipiravir (FPV), the active metabolite of brincidofovir, cidofovir (CDF)), and the estrogen receptor modulator, toremifene (TOR), in inhibiting viral replication in dose-response and time course studies. We also tested 28 two- and 56 three-drug combinations against Ebola replication. IFN-α and IFN-ß inhibited viral replication 24 hours post-infection (IC50 0.038μM and 0.016μM, respectively). 3TC, AZT and TFV inhibited Ebola replication when used alone (50-62%) or in combination (87%). They exhibited lower IC50 (0.98-6.2μM) compared with FPV (36.8μM), when administered 24 hours post-infection. Unexpectedly, CDF had a narrow therapeutic window (6.25-25μM). When dosed >50μM, CDF treatment enhanced viral infection. IFN-ß exhibited strong synergy with 3TC (97.3% inhibition) or in triple combination with 3TC and AZT (95.8% inhibition). This study demonstrates that IFNs and viral polymerase inhibitors may have utility in EVD. We identified several 2 and 3 drug combinations with strong anti-Ebola activity, confirmed in studies using fully infectious ZEBOV, providing a rationale for testing combination therapies in animal models of lethal Ebola challenge. These studies open up new possibilities for novel therapeutic options, in particular combination therapies, which could prevent and treat Ebola infection and potentially reduce drug resistance." @default.
• W2236504019 created "2016-06-24" @default.
• W2236504019 creator A5005621215 @default.
• W2236504019 creator A5013833343 @default.
• W2236504019 creator A5013946002 @default.
• W2236504019 creator A5019795131 @default.
• W2236504019 creator A5040888166 @default.
• W2236504019 creator A5051652706 @default.
• W2236504019 creator A5059344072 @default.
• W2236504019 creator A5070868227 @default.
• W2236504019 creator A5076213121 @default.
• W2236504019 date "2016-01-11" @default.
• W2236504019 modified "2023-10-01" @default.
• W2236504019 title "A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus" @default.
• W2236504019 cites W1971292277 @default.
• W2236504019 cites W1974225087 @default.
• W2236504019 cites W1980461546 @default.
• W2236504019 cites W1985403315 @default.
• W2236504019 cites W1993332077 @default.
• W2236504019 cites W2029424710 @default.
• W2236504019 cites W2049287879 @default.
• W2236504019 cites W2053804496 @default.
• W2236504019 cites W2056956872 @default.
• W2236504019 cites W2058814593 @default.
• W2236504019 cites W2060087439 @default.
• W2236504019 cites W2072202424 @default.
• W2236504019 cites W2076340825 @default.
• W2236504019 cites W2076506726 @default.
• W2236504019 cites W2077661149 @default.
• W2236504019 cites W2084011352 @default.
• W2236504019 cites W2094993149 @default.
• W2236504019 cites W2103562758 @default.
• W2236504019 cites W2109986071 @default.
• W2236504019 cites W2112895187 @default.
• W2236504019 cites W2117107646 @default.
• W2236504019 cites W2122522262 @default.
• W2236504019 cites W2122527653 @default.
• W2236504019 cites W2130901375 @default.
• W2236504019 cites W2134966461 @default.
• W2236504019 cites W2150837053 @default.
• W2236504019 cites W2155205118 @default.
• W2236504019 cites W2164859440 @default.
• W2236504019 cites W2169230097 @default.
• W2236504019 cites W2171288645 @default.
• W2236504019 cites W2256071216 @default.
• W2236504019 cites W2299605201 @default.
• W2236504019 doi "https://doi.org/10.1371/journal.pntd.0004364" @default.
• W2236504019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4709101" @default.
• W2236504019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26752302" @default.
• W2236504019 hasPublicationYear "2016" @default.
• W2236504019 type Work @default.
• W2236504019 sameAs 2236504019 @default.
• W2236504019 citedByCount "46" @default.
• W2236504019 countsByYear W22365040192016 @default.
• W2236504019 countsByYear W22365040192017 @default.
• W2236504019 countsByYear W22365040192018 @default.
• W2236504019 countsByYear W22365040192019 @default.
• W2236504019 countsByYear W22365040192020 @default.
• W2236504019 countsByYear W22365040192021 @default.
• W2236504019 countsByYear W22365040192022 @default.
• W2236504019 countsByYear W22365040192023 @default.
• W2236504019 crossrefType "journal-article" @default.
• W2236504019 hasAuthorship W2236504019A5005621215 @default.
• W2236504019 hasAuthorship W2236504019A5013833343 @default.
• W2236504019 hasAuthorship W2236504019A5013946002 @default.
• W2236504019 hasAuthorship W2236504019A5019795131 @default.
• W2236504019 hasAuthorship W2236504019A5040888166 @default.
• W2236504019 hasAuthorship W2236504019A5051652706 @default.
• W2236504019 hasAuthorship W2236504019A5059344072 @default.
• W2236504019 hasAuthorship W2236504019A5070868227 @default.
• W2236504019 hasAuthorship W2236504019A5076213121 @default.
• W2236504019 hasBestOaLocation W22365040191 @default.
• W2236504019 hasConcept C126322002 @default.
• W2236504019 hasConcept C140704245 @default.
• W2236504019 hasConcept C142462285 @default.
• W2236504019 hasConcept C159047783 @default.
• W2236504019 hasConcept C2522874641 @default.
• W2236504019 hasConcept C2776824251 @default.
• W2236504019 hasConcept C2777469322 @default.
• W2236504019 hasConcept C2777869810 @default.
• W2236504019 hasConcept C2779134260 @default.
• W2236504019 hasConcept C2779756493 @default.
• W2236504019 hasConcept C2779772310 @default.
• W2236504019 hasConcept C2780216070 @default.
• W2236504019 hasConcept C2780593183 @default.
• W2236504019 hasConcept C2780727368 @default.
• W2236504019 hasConcept C2909623084 @default.
• W2236504019 hasConcept C3008058167 @default.
• W2236504019 hasConcept C524204448 @default.
• W2236504019 hasConcept C71924100 @default.
• W2236504019 hasConcept C86803240 @default.
• W2236504019 hasConcept C98274493 @default.
• W2236504019 hasConceptScore W2236504019C126322002 @default.
• W2236504019 hasConceptScore W2236504019C140704245 @default.
• W2236504019 hasConceptScore W2236504019C142462285 @default.
• W2236504019 hasConceptScore W2236504019C159047783 @default.
• W2236504019 hasConceptScore W2236504019C2522874641 @default.
• W2236504019 hasConceptScore W2236504019C2776824251 @default.

• next